Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

The incidence and prevalence of inflammatory bowel disease (IBD) are increasing
worldwide. Current approved medication for IBD treatment in the clinic mainly includes …

The intestinal microbiome is a key determinant of responses to biologic therapy in
inflammatory bowel disease (IBD). However, diverse therapeutics and variable responses …

Fatigue is a burdensome, multidimensional, and multifactorial symptom that is associated
with a wide array of chronic illnesses, specifically occurring in nearly 50% of patients with …

Although there are number of available therapies for ulcerative colitis (UC), many patients
are unresponsive to these treatments or experience secondary failure during treatment …

Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD)
characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory …

Intestinal inflammation and microbiota are two important components of colorectal cancer
(CRC) etiology. However, it is not clear how tuning inflammation using clinically relevant anti …

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis
and Crohn's disease. Although having a common global pathophysiological mechanism …

Loss of response to therapy in inflammatory bowel disease (IBD) has led to a surge in
research focusing on precision medicine. Three systematic reviews have been published …

Background Inflammatory bowel disease (IBD) is a chronic relapsing-remitting disease. An
adverse immune reaction toward the intestinal microbiota is involved in the pathophysiology …